Creyon: Biotech Startup Teams Up with Eli Lilly in Strategic Partnership
Deal News | Apr 29, 2025 | DCVC Management Co LLC
Creyon Bio, a San Diego-based biotech startup focused on oligonucleotides, has announced its first major partnership with pharma giant Eli Lilly. The collaboration marks a significant milestone for Creyon, providing the small biotech company with increased resources and expertise to advance its oligonucleotide research and development efforts. Eli Lilly's involvement further validates Creyon's innovative platform in oligonucleotide therapies, potentially accelerating groundbreaking treatments. This strategic alliance is facilitated by DCVC Management Co LLC, the private equity firm backing Creyon. With the recent appointment of a new CEO at Creyon, the company is positioned to capitalize on the synergies this partnership could foster.
Sectors
- Biotechnology
- Pharmaceuticals
- Private Equity
Geography
- United States – Creyon Bio is based in San Diego, California, and Eli Lilly is headquartered in Indianapolis, Indiana, both located in the United States.
Industry
- Biotechnology – The article revolves around Creyon Bio, which operates in the biotechnology sector, focusing on the development of oligonucleotide therapies.
- Pharmaceuticals – With Eli Lilly as a key partner, the article touches on the pharmaceutical industry's role in advancing biotech innovations.
- Private Equity – DCVC Management Co LLC’s involvement as the private equity firm backing Creyon Bio highlights the sector's interest in evolving biotech businesses.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Creyon Bio | Biotech Company; Target Company | Company | A biotechnology startup focused on developing oligonucleotide therapies. |
| Eli Lilly | Pharmaceutical Partner | Company | A major pharmaceutical company partnering with Creyon Bio to advance oligonucleotide research. |
| DCVC Management Co LLC | Private Equity Firm; Investor | Company | The private equity firm backing Creyon Bio. |